Outside of de novo high volume metastatic #ProstateCancer situation, #APCCC24 voting results on who could/should get a triplet…

Advanced Prostate Cancer Consensus Conference

This marks a significant step forward in personalized cancer treatment. #PrecisionOncology

Congratulations 👏👏👏

With the rise of antibody-drug conjugates, precise biomarker identification is key to revolutionizing care. #CancerResearch #PersonalizedMedicine #ClinicalOncology 🧬💊🔬

Somethings a Brewin here in Lugano🇨🇭
Live from #APCCC24
Uromigos GU Cast | Urology podcast! OncoAlert 🚨
WEBCAST...Coming Soon‼️

Declan Murphy 🇦🇺
Renu Eapen 🇦🇺
Brian Rini, MD 🇺🇸
Tom Powles 🇬🇧
Gil Morgan, MD 🇺🇸

Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas…

Spotlight on #APCCC24 : Dr. Vedang Murthy from Tata Memorial Hospital
Addressing disparities head-on, we're inspired by initiatives that promise to turn the tide in #prostatecancer care. 🏥✨🌍

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro…

At #APCCC24 , Stacy Loeb, MD highlights the transformative role of AI and social media in global prostate cancer care—promising for LMICs, cost-effective, and beneficial clinically, yet emphasizing the need for accurate, equitable information. #GlobalHealth 🌍💡
#APCCC24 Advanced Prostate Cancer Consensus Conference…

3 million cases of prostate ca will be diagnosed per year by 2040.

Fascinating session on global prostate cancer control Advanced Prostate Cancer Consensus Conference

#radonc is a key part of the solution. 200 more machines needed in Nigeria alone.

Targeting Cancer The Global Coalition for Radiotherapy ESTRO ASTRO IAEA - International Atomic Energy Agency ⚛️

An Amazing DAY2⃣of #APCCC24
Grateful to Advanced Prostate Cancer Consensus Conference silke gillessen
aurelius omlin and Team🇨🇭 for the AMAZING efforts that led to this GREAT meeting in #ProstateCancer

✅2⃣1⃣MILLION Impressions
✅OVER 3⃣.3⃣K Tweets
✅OncoAlert Faculty 1⃣4⃣.5⃣ million impressions

Dra. María Natalia Gandur Quiroga…

Enhancing diagnosis, integrating prostate cancer care with men’s health, and empowering patients to make informed decisions are top priorities.
#apccc24 Advanced Prostate Cancer Consensus Conference The Lancet Movember USA Prostate Cancer Foundation #prostate #cancer #oncology

Art meets science: Exploring the frontiers of science and medicine!
The APCCC conference convenes under the watchful eyes of history and innovation.
#APCCC24 Advanced Prostate Cancer Consensus Conference OncoAlert

Who is suitable for bladder sparing treatment in 2024?

Join us & discuss with Prof Ananya💙 from The Christie NHS in presence or virtually!

Register for free 👉ow.ly/SrwS50Rp9W2

#IUCS24 #urology #bladdercancer Giuseppe Banna Ravindran Kanesvaran

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 Majority of panelists favor using PARPi ( mono or combinations) in metastatic #prostatecancer beyond BRCA2 mutations👉in BRCA1, ATM, RAD51C, PALB2, & CDK12 mutations OncoAlert silke gillessen Oncology Brothers

Great point made in comments. Metastatic cancer is a marathon, not a sprint. Often quality of life concerns must be considered. What treatment helps the patient FEEL the best for the longest time? #APCCC24 #patientadvocacy

AN AMAZING TWEETORIAL
SUM Up of FIRST DAY OF #APCCC24 🇨🇭
Author: #OncoAlertAF Dra. María Natalia Gandur Quiroga 🇦🇷

Pinging OncoAlert 🚨GU faculty
Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas Tian Zhang, MD, MHS Hans Hammers Ravindran Kanesvaran Neeraj Agarwal, MD, FASCO Axel S. Merseburger…

In first-line mCRPC with BRCA2 mutation, PARP inhibitor addition is preferred post-ADT+ARPI+docetaxel. What shifts the choice towards PARP inhibitors in this scenario?

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD…

In mCRPC with BRCA2 mutation after initial ADT+docetaxel, ARPI plus PARP inhibitor is the favored treatment. How does BRCA2 status alter management strategy?

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD…

For mCRPC patients who began first-line treatment with ADT+ARPI+docetaxel, the primary subsequent option is 177Lu-PSMA, whether DDR alterations are present or not. What considerations guide the transition to 177Lu-PSMA therapy?

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin…

For mCRPC patients previously treated with ADT+ARPI, the main treatment recommendation is docetaxel, regardless of DDR alterations.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James Christopher Sweeney, MBBS…